吉西他滨联合顺铂治疗晚期复发性卵巢癌18例疗效观察

Gemcitabine Combined with Cisplatin in the Treatment of 18 Cases with Recurrent Ovarian Cancer

[目的]评价吉西他滨联合顺铂（GP方案）对多线化疗失败的晚期复发性卵巢癌的疗效及不良反应。[方法]回顾性分析18例接受GP方案化疗的晚期复发性卵巢癌患者,结合实体瘤疗效评估标准评价其临床疗效和安全性。[结果]GP方案化疗2个周期后,无完全缓解,部分缓解3例,病情稳定4例,进展11例,临床缓解率为16.7%（3/18）,疾病控制率为38.9%（7/18）;铂类敏感型与铂类耐药型复发患者的疾病控制率比较差异无统计学意义（P〉0.05）。PFS为1.3~7.7个月,中位PFS为2.0个月。生存质量控制率为83.3%。主要不良反应为骨髓抑制及胃肠道反应。[结论]GP方案对多线化疗失败的晚期复发性卵巢癌具有一定疗效,能够改善患者生存质量,且耐受性较好,不良反应小。

[ Objective ] To evaluate the effects of chemotherapy regimen of gemcitabine and cisp｜atin（GP regimen） in the treatment of advanced recurrent ovarian cancer with multi-line chemotherapy failure. [ Methods] A retrospective analysis of 18 patients with advanced recurrent ovarian cancer treated with GP chemotherapy regimen. The clinical efficacy and security were evaluated by combining the efficacy evaluation criteria of solid tumors. [Results] After two cycles treatment of GP chemotherapy regimen, CR 0 case,PR 3 cases,SD 4 cases,and PD 11 cases. The objective response rate was 16.7%（3/18）, disease control rate was 38.9%（7/18）. There was no significant differences between the platinum-sensitive and platinum-resistant patients with recurrent at disease control rate （P〉0.05）. PFS was 1.3-7.7 months and the median PFS was 2.0 months. The control rate of QOL was 83.3%. The main adverse reactions were myelosuppression and gastrointestinal reactions. [Conclusion] GP regimen has a certain efficacy in the treatment of advanced recurrent ovarian cancer with multi-line chemotherapy failure. It can improve the quality of life of patients, and has good tolerability and little adverse effects.